Whereas the connection between HER2 amplification (detected by fluorescence in situ hybridization) and overexpression (observed e.g., in breast cancer) remains less clear in NSCLC60, HER2 amplification is observed de novo in 3% of lung adenocarcinomas57 or is acquired in 13% of patients after failure of targeted therapy61. The gene discussed is ERBB2; the disease is breast carcinoma.